Advancing Biopharma, R&D Innovation, Decision Making & Operations

A conference for biopharma executives at the intersection of science, business, and operations

In a new, post-pandemic landscape, it is more important than ever for pharma, biotech, and device companies to reevaluate their strategy and portfolios, improve decision making, minimize risk, and effectively deploy resources. Cambridge Healthtech Institute’s BioPharma Strategy Series present Executive Decision Making 2021 Virtual, 3 full days of high-level content, interactive discussions and networking, breakout roundtables, 1:1 meetings, and much more! Attendees will leave with new strategies and tools to navigate the highly competitive and challenging drug development landscape.

Register Early for maximum savings! >

Now Virtual!

Like many of you, we have been closely following updates and evolving guidance from local, national and global agencies for COVID-19. There is still much uncertainty around the coronavirus, and how long our communities may be impacted by the pandemic, but it seems certain that decisions about how we work, travel and gather together will continue to be influenced for weeks and months still to come.

Our interactive, engaging virtual platform enables face to face networking, smaller group breakout rooms, live polling, gaming, virtual exhibits and much more. Plus, you can access the full program on demand for a full year ager the event takes place. We may not be able to gather in person yet, but don’t let that stop your career development, education and peer interactions!

In light of evolving updates and concerns around the coronavirus, we are excited to announce that our 2021 event will be virtual: Executive Decision Making Virtual, May 18-20, 2021.

This event has always been a great opportunity to bring the biopharma executive community together. Until we are able to join in person we are excited to move forward virtually in 2021. We thank all of our stakeholders for their support in these uncertain times, and hope to work with all of you again in the future.

DOWNLOAD FINAL AGENDA PDF

BREAKOUT DISCUSSIONS

VIEW MEDIA PARTNERS

Premier Sponsor

Featured Speakers

Cleat Jerden,

Executive Director, Business Performance, Business Analysis and External Process Development, Amgen

Daniel Patrick,

Global Group Leader, R&D Program Management Office and Portfolio Management, Daiichi Sankyo

John Shirley,

Director, Worldwide Research Development & Medical (WRDM), Pfizer

Keely Zipp,

Vice President, Corporate Development & Portfolio Strategy, Lava Therapeutics

MEETINGS LIKE THESE ARE VERY HELPFUL FOR ADVANCING THE COLLECTIVE PRODUCTIVITY OF THE INDUSTRY, AND IN SO DOING, HELP EVERYONE BY ENABLING AND EXPEDITING THE DEVELOPMENT OF NEW MEDICINES FOR THE PATIENTS THAT NEED THEM.

- Vice President, WRD Business Operations, Pfizer, Inc.

Featured Presentation

This presentation will examine the evolution of Portfolio Management in the BioPharma industry by addressing the following questions:

How different is 21st century Portfolio Management from that of the last quarter of the 20th century?
When and where should Portfolio Management begin and how should trade-off decisions be made between competing investments?
Why is Decision Analysis often viewed as the ugly step-sibling of Portfolio Management?
Where do most organizations find themselves on the Portfolio Management capability maturity curve?
What does it take to build sustainable excellence in Portfolio Management?

Our Virtual Event Platform

Pathable is a robust event platform, designed to enhance the online conference experience and selected by CHI for its full range of opportunities to present, target, connect and expand your reach.

Learn More